Mechanistically, the study revealed that oncogenic activation of MYC impaired IFN-γ–mediated transcriptional activation by downregulating JAK2 (65), suggesting the potential of MYC as a predictive biomarker of SCLC immunotherapy, which needed to be supported by more studies on the mechanism of MYC regulating SCLC immunity. The gene discussed is MYC; the disease is small cell lung carcinoma.